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Abstract:  Cisplatin, an anticancer drug, is well known to have nephrotoxicity as an adverse effect.  We investigated
the expressions of cell cycle markers and prostaglandin E2 (PGE2) receptors (EP) in the affected renal tubules in rats
injected with a single dose (6 mg/kg body weight) of cisplatin.  On days 1–3 after dosing, the affected renal epithelial
cells were almost desquamated, showing necrosis.  On day 5 onwards, the renal tubules were rimmed by flattened or
cuboidal epithelial cells with basophilic cytoplasm; BrdU-immunopositive cells began to significantly increase,
indicating regeneration.  Simultaneously, TUNEL-positive apoptotic cells were also seen.  On days 1–5, cyclin D1-
immunopositive cells were decreased with an increased expression in p21 mRNA, indicating G1 arrest in the cell cycle.
The affected renal epithelial cells began to react to EP4 receptor, but not to EP2 receptor.  Some EP4 receptor-reacting
epithelial cells gave a positive reaction to BrdU or cyclin D1.  Collectively, the affected renal tubules underwent various
alterations such as necrosis, apoptosis, regeneration and G1 arrest; the aspects might be influenced by endogenous PGE2
through EP4 receptor.  (J Toxicol Pathol 2010; 23: 271–275)
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Cis-diamminedichloroplatinum (CDDP; cisplatin) has
been widely used as an anticancer drug; it is well known to
have nephrotoxicity1.  The primary injury resulting from
CDDP occurs in the proximal renal tubules in the cortico-
medullary junction.  Previously, we have shown that rats
treated with a high dose of CDDP are useful for studies on
the pathogenesis of renal tubular alterations after injury2.
The affected epithelial cells have the capacity to regenerate;
however, incomplete regeneration occurs when the basal
lamina is completely damaged.  The pathological alterations
of the affected renal tubules in CDDP-treated rats remain to
be investigated.
Recently, it has been shown that endogenous prostag-
landin (PG) plays an important role in the pathophysiology
of the kidneys3.  PGE2, the main type of PG produced in the
kidney, has been reported to be associated with renal hemo-
dynamics and water and salt excretion3, 4.  PGE2 also influ-
ences cell proliferation and differentiation mainly through
PG receptor (EP) 2 or EP45–7.  In the present study, we inves-
tigated the epithelial alterations in CDDP-treated rat kidneys
using cell cycle markers and pursued the relationship
between the expressions of cell cycle markers and EP recep-
tors.
The present animal experiments were conducted
according to the authors’ institutional guidelines for animal
care.  Thirty-two 6-week-old male F344/DuCrj rats (Charles
River Japan, Hino, Shiga, Japan), weighing 125–150 g, were
used after a one-week acclimatization period.  Of them, 28
rats were injected with CDDP (Nippon Kayaku Co., Ltd.,
Tokyo, Japan) at a single dose of 6 mg/kg body weight intra-
peritoneally, and four animals were sacrificed each on days
1, 3, 5, 7, 9, 12 and 15 after CDDP dosing.  The remaining
four rats were injected with saline (control) and sacrificed on
day 0.  All animals received intraperitoneal injection of 5’-
bromo-2’-deoxyuridine (BrdU, 50 mg/kg body weight) one
hour before sacrifice.
The renal tissues were fixed in 10% neutral buffered
formalin or periodate-lysine-paraformaldehyde (PLP) fixa-
tives.  Formalin-fixed specimens were processed routinely
for morphological evaluation.  PLP solution-fixed speci-
mens were embedded in paraffin by the AMeX method
(PLP-AMeX method)8.  The specimens made by the PLP-
AMeX method were stained immunohistochemically with
monoclonal antibodies to cyclin D1 (1:200; Upstate Biotech-
nology Inc., Lake Placid, NY, USA) and BrdU (1:100;
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DAKO Denmark A/S, Glostrup, Denmark), as well as poly-
clonal antibodies to EP2 receptor (1:500; Cayman Chemical
Co., Ann Arbor, MI, USA) and EP4 receptor (1:500; Upstate
Biotechnology Inc., Woburn, MA, USA).  Tissue sections
were incubated with the primary antibody overnight (12–14
hr) at 4°C.  Thereafter, sections were incubated for 45 min
with the secondary antibody (Histofine Simple Stain MAX
PO; Nichirei Corporation, Tokyo, Japan).  Positive reactions
were visualized with 3, 3’-diaminobenzidine (DAB).  Sec-
tions were lightly counterstained with hematoxylin.
Double immunohistochemical stainings were per-
formed using antibodies for EP4 receptor and cyclin D1.  At
the first reaction, sections were incubated with the anti-EP4
receptor primary antibody.  After visualization with DAB
(brown in color), sections were washed with water and then
incubated with the anti-cyclin D1 primary antibody over-
night at 4°C at the second reaction.  The sections were then
incubated with EnVision-alkaline phosphatase (DAKO).
The positive reactions at the second reaction were visualized
as red with a Fuchsin substrate (DAKO).  To identify renal
epithelial cells coexpressing EP4 receptor and BrdU (S
phase in the cell cycle), immunohistochemical stainings with
antibodies for EP4 receptor and BrdU were performed using
serially cut sections.
For detection of DNA fragmentation for apoptotic cells,
the standard in-situ TdT-mediated dUTP-biotin Nick End
Labeling (TUNEL: ApopTag® Peroxidase In Situ Apoptosis
Detection Kit; Chemicon International Inc, Temecula, CA,
USA) method was used according to the manufacturer’s
instructions.
The number of cells reacting to cyclin D1, BrdU or
TUNEL was counted in five randomly selected areas at a
magnification of ×400 in the cortico-medullary junction.
The immunoreactivities for the EP2 and EP4 receptors were
assessed semiquantitatively as follows: –, no change; ±,
faintly positive staining; 1+, moderately positive staining;
2+, more clearly evident staining; and 3+, markedly positive
staining.
Total RNA was extracted from renal tissues with Trizol
ReagentTM (Invitrogen Corp., Carlsbad, CA, USA) and a SV
Total RNA Isolation System (Promega, Osaka, Japan).  The
RNA was reverse transcribed to cDNA using a SuperScript
First-Strand Synthesis SystemTM (Invitrogen).  All PCR
experiments were performed with SYBR Green Real-time
PCR Master Mix (Toyobo Co., Ltd., Life Science Depart-
ment, Osaka, Japan)9.  The amplification program consisted
of 1 cycle at 95°C with a 1-min hold followed by 45 cycles
at 95°C with a 15-sec hold, annealing at 60°C for p21 (one of
the cyclin-dependent kinase inhibitors) and at 62°C for
cyclin D1 with a 15-sec hold and 72°C with a 30-sec hold.
Melting curve analysis to verify the accuracy of the PCR
products followed amplification.  The PCR primer
sequences for cyclin D1 were 5'-TGGAGCCCCTGAA-
GAAGAG-3' (forward) and 5'-AAGTGCGTTGTGCGG-
TAGC-3' (reverse).  The sequences for p21 were 5'-
CAAAGTATGCCGTCGTCTGTT-3' (forward) and 5'-
GCTGGTCTGCCTCCGTTTTC-3' (reverse).  The relative
expression values were normalized to the expression value
of β-actin10.  Values were calculated by the comparative Ct
method.  Data are presented as means ± standard deviation
(SD).  Values of P<0.05 were considered significant.  Differ-
ences between the control and CDDP-injected groups were
evaluated by analysis of variance (ANOVA).  
Histopathologically, renal tubules in the cortico-medul-
lary junction, mainly in the P3 segment of the proximal
Fig. 1.  The kinetics of positive cells to 5'-bromo-2'-deoxyuridine
(BrdU) (A), the standard in-situ TdT-mediated dUTP-biotin
Nick End Labeling (TUNEL) method (B) and cyclin D1 (C).
The symbol and whisker represent the mean and standard
deviation, respectively.  A: The number of BrdU-positive
cells gradually increases from day 1, peaking on day 5; on
days 5, 7, 12 and 15, the number shows a significant increase.
B: The number of apoptotic cells, demonstrable by the
TUNEL method, exhibits a significant transient increase on
day 5.  C: The cyclin D1-positive cell number begins to
decrease from day 1 and remains decreased until day 15;
on days 3 and 15, the number shows a significant decrease.
* P<0.05 compared with the controls (day 0).Yamamoto, Izawa, Juniantito et al. 273
Fig. 2. BrdU and cyclin D1-immunopositive cells in CDDP-treated rat kidneys.  A: BrdU stain on day 5; arrowheads indicate BrdU-positive cells
in cuboidal epithelial cells of the affected renal tubules.  B: Cyclin D1 stain on day 9; arrowhead indicates the positive reaction in the
dilated tubules.  Immunohistochemical staining counterstained with hematoxylin.  Bar=50 μm.
Fig. 4. Immunohistochemistry for EP4 receptor in the kidneys of
CDDP-injected rats.  On day 7, the epithelial cells in the
affected renal tubules react strongly to EP4 receptor (arrow-
heads) in the cortico-medullary junction.  Immunohistochem-
ical staining counterstained with hematoxylin.  Bar=50 μm.
Fig. 5. Double immunostaining for cyclin D1 and EP4 receptor from
renal samples on day 9.  Cyclin D1 is visualized with fuchsin
(red) and EP4 receptor is stained with DAB (brown).  Some
cyclin D1 positive cells are also positive for EP4 receptor
antibody (arrowhead).  Immunohistochemical staining
counterstained with hematoxylin.  Bar=50 μm.
Fig. 6. Serial sections of immunostainings for EP4 receptor (A) and BrdU (B) from renal samples on day 9.  A: Immunoreaction for EP4 receptor
in flattened or cuboidal epithelial cells of the affected tubules.  B: Immunoreaction for BrdU in cuboidal epithelial cells of the regenerating
renal tubules.  Arrowheads indicate representative cells positive for both EP4 receptor and BrdU.  Immunohistochemical staining
counterstained with hematoxylin.  Bar=50 μm.274 Regeneration and PGE2 Receptor Expression in Cisplatin-induced Rat Renal Failure 
tubules, were injured by CDDP.  On days 1 and 3, desqua-
mation of damaged epithelial cells into the tubular lumina
was seen.  In addition to the necrotic changes, on days 5 and
7, the affected renal tubules were variously dilated and con-
tained desquamated epithelial cells.  On days 7, 9, 12 and 15,
the affected renal tubules were rimmed by flattened, polygo-
nal or cuboidal epithelial cells that appeared to be regenerat-
ing epithelial cells; interstitial fibrosis developed around the
affected tubules.  These findings agreed with those in a pre-
vious report2.
Immunohistochemically, the number of cells reacting to
BrdU increased significantly on days 5–15, peaking on day 5
(Figs. 1A, 2A).  BrdU immunopositive cells were observed
mainly in cuboidal cells of the affected renal tubules.  Simul-
taneously, the TUNEL-positive apoptotic cell number exhib-
ited a significant transient increase on day 5 (Fig. 1B).
TUNEL-positive cells were observed in epithelial cells of
the dilated tubules containing desquamated epithelial cells.
On the other hand, the cyclin D1-positive cell number tended
to be decreased in the CDDP-treated kidneys on days 1–15
(Fig. 1C); although the number of positive cells was
decreased, stronger expression compared with the controls
was observed after CDDP injection, especially from day 7
onwards; the expression was observed exclusively in flat-
tened or cuboidal epithelial cells of the dilated renal tubules,
which appeared to be regenerating cells after desquamation
(Fig. 2B).  A similar tendency to decrease was confirmed by
the real-time RT-PCR (Fig. 3A).  The p21 mRNA analysis
showed a significant increase on days 1–5 after CDDP injec-
tion (Fig. 3B).
No positive reaction to EP2 receptor was seen in the
control kidneys (–).  Although epithelial cells of some renal
tubules in the medulla and papilla showed a positive reaction
to EP2 receptor (± or +), no reaction to EP2 receptor was
observed in the affected tubules of the CDDP-injected rats (–
).  In the control kidneys, epithelial cells of the proximal
renal tubules did not show any positive reaction to EP4
receptor (–); interestingly, in the CDDP-injected rats, a posi-
tive reaction to EP4 receptor began to be seen in flattened or
cuboidal epithelial cells of the affected renal tubules on day
7, and positive reactions were observed on subsequent days
(2+ or 3+; Fig. 4).
The double immunohistochemical staining revealed
that there were EP4 receptor-positive cells expressing cyclin
D1 (Fig. 5).  On serial sections, some renal epithelial cells
coexpressing BrdU and EP4 receptor were identified (Fig. 6,
arrowheads).  
Cyclin D1 is a regulator acting in the G1 phase12.  The
loss of cyclin D1 expression and the increase of p21 expres-
sion have been considered to be a feature of cell cycle
arrest12, 13.  Since CDDP causes DNA damage12, 14, which has
been considered one of the causes of cell cycle arrest, the
changes of p21 and cyclin D1 expressions might be due to
the toxic effect of CDDP.  On the other hand, there were
cells reacting strongly to cyclin D1 in the affected renal
tubules, particularly from day 7 onwards; these cells were
characterized morphologically by flattened or cuboidal epi-
thelial cells with basophilic cytoplasm, indicating regenera-
tion.  Since cyclin D1 plays a role in exit from the quiescence
period15, the cells observed to be expressing cyclin D1
strongly on day 7 onwards might reentry the cell cycle, an
important step for regeneration16.  More interestingly,
TUNEL-positive apoptotic cells were also significantly
increased on day 5.  It has been reported that G1 arrest is a
stage in which the fate of affected cells, proliferation or apo-
ptosis can be determined14.  The simultaneous presence of
BrdU- and TUNEL-positive cells on day 5 might imply that
there was a critical point between regeneration and apoptosis
in the affected renal tubules; the mechanisms remain to be
investigated in the future.  Collectively, it was considered
that the affected renal epithelial cells underwent various
pathological alterations such as necrosis, apoptosis, active
regeneration and G1 arrest.
Endogenous PGE2 plays important roles in cellular pro-
liferation and differentiation in injured renal tubules7, 17–19.
These functions act through elevation of cAMP7.  In the
present study, no immunoreaction to EP2 receptor was seen
in the affected renal tubules in the CDDP-injected rats.  On
the other hand, EP4 receptor immunoexpression began to be
seen in the affected renal tubules.  Because some cells react-
ing to EP4 receptor showed a positive reaction to BrdU or
cyclin D1, EP4 receptor expression might be involved in cel-
lular alterations of the affected renal tubules.
In conclusion, the present study showed that CDDP-
injured renal epithelial cells underwent various pathological
Fig. 3. mRNA expressions of cyclin D1 (A) and p21 (B) by the real-
time RT-PCR method.  The symbol and whisker represent the
mean and standard deviation, respectively.  A: The
expression of cyclin D1 mRNA significantly decreases on
days 5 to 12.  B: The expression of p21 mRNA significantly
increases on days 1 to 5.  * P<0.05 compared with the
controls (day 0).Yamamoto, Izawa, Juniantito et al. 275
alterations.  Endogenous PGE2 might be attributable to such
aspects through upregulated EP4 receptor expression.
Because of these complicated renal tubular changes, the
regeneration of epithelial cells might be incomplete, presum-
ably leading to progressive interstitial fibrosis in CDDP-
injured kidneys2.  It would be interesting to pursue the rela-
tionship between renal alteration and interstitial fibrosis.
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